tiprankstipranks
Advertisement
Advertisement

GRAL Stock Latest News

Grail Inc Earnings Call Highlights Growth Amid Risks
Company AnnouncementsGrail Inc Earnings Call Highlights Growth Amid Risks
1d ago
GRAL
Grail announces FDA advisory committee meeting to review Galleri test PMA
PremiumThe Fly
Grail announces FDA advisory committee meeting to review Galleri test PMA
16d ago
GRAL
Grail reports Q2 EPS ($2.56), consensus ($2.43)
PremiumThe Fly
Grail reports Q2 EPS ($2.56), consensus ($2.43)
17d ago
GRAL
Grail’s Gallery cancer detection test adopted by Priority Health
PremiumThe Fly
Grail’s Gallery cancer detection test adopted by Priority Health
1M ago
GRAL
Grail price target raised to $88 from $69 at TD Cowen
PremiumThe Fly
Grail price target raised to $88 from $69 at TD Cowen
1M ago
GRAL
Grail price target raised to $65 from $58 at Mizuho
PremiumThe FlyGrail price target raised to $65 from $58 at Mizuho
1M ago
GRAL
GRAIL Shareholders Reelect Directors and Ratify Auditor
Premium
Company Announcements
GRAIL Shareholders Reelect Directors and Ratify Auditor
2M ago
8K
GRAL
Grail Faces Federal Securities Lawsuit After NHS-Galleri Trial Falls Short and Stock Drops Over 50% 
Premium
Class Action
Grail Faces Federal Securities Lawsuit After NHS-Galleri Trial Falls Short and Stock Drops Over 50% 
2M ago
GRAL
Grail initiated with a Neutral at Goldman Sachs
PremiumThe Fly
Grail initiated with a Neutral at Goldman Sachs
3M ago
GRAL
Grail assumed with a Peer Perform at Wolfe Research
PremiumThe Fly
Grail assumed with a Peer Perform at Wolfe Research
3M ago
GRAL
GRAIL Names Joshua Ofman CEO, Enhances Leadership Compensation
PremiumCompany Announcements
GRAIL Names Joshua Ofman CEO, Enhances Leadership Compensation
3M ago
8K
GRAL
Grail falls -15.6%
PremiumThe Fly
Grail falls -15.6%
3M ago
GRAL
Grail falls -18.4%
PremiumThe FlyGrail falls -18.4%
3M ago
GRAL
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
Premium
The Fly
Grail presents ‘positive’ performance, safety results from Pathfinder 2 study
3M ago
GRAL
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
Premium
The Fly
Grail reports results from NHS-Galleri trial in presentation at ASCO meeting
3M ago
GRAL
Grail Inc. Earnings Call Highlights Growth Amid Risks
PremiumCompany Announcements
Grail Inc. Earnings Call Highlights Growth Amid Risks
3M ago
GRAL
Grail price target lowered to $70 from $82 at Baird
PremiumThe Fly
Grail price target lowered to $70 from $82 at Baird
4M ago
GRAL
Grail price target raised to $56 from $54 at Piper Sandler
PremiumThe Fly
Grail price target raised to $56 from $54 at Piper Sandler
4M ago
GRAL
Grail price target raised to $69 from $65 at TD Cowen
PremiumThe Fly
Grail price target raised to $69 from $65 at TD Cowen
4M ago
GRAL
Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69
PremiumRatingsDaniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69
4M ago
GRAL
Grail reports Q1 EPS ($2.29), consensus ($1.96)
Premium
The Fly
Grail reports Q1 EPS ($2.29), consensus ($1.96)
4M ago
GRAL
Grail initiated with a Neutral at Mizuho
Premium
The Fly
Grail initiated with a Neutral at Mizuho
4M ago
GRAL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >